BLAINJECTIONINJECTABLE
Approved
Mar 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
4/8 — Partial
TALTZ (ixekizumab) by Eli Lilly and Company is interleukin-17a antagonists [moa]. Approved for interleukin-17a antagonist [epc]. First approved in 2016.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALTZ (ixekizumab) is a monoclonal antibody that selectively inhibits interleukin-17A, a key cytokine in inflammatory and autoimmune pathways. It is approved for six indications spanning plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and severe pustular and erythrodermic psoriasis. The drug works by binding and neutralizing IL-17A, reducing the inflammatory cascade responsible for these conditions.
Peak
TALTZ is at peak commercial stage with moderate competitive pressure (30/100), indicating sustained market investment and stable brand team headcount in core commercial roles.
Mechanism of Action
Interleukin-17A Antagonists
Pharmacologic Class:
Interleukin-17A Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects
Started Sep 2025
218 enrolled
Healthy Participants
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Started Mar 2025
200 enrolled
PsoriasisOverweight or Obesity
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Started Mar 2025
200 enrolled
Psoriatic ArthritisOverweight or Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Started Sep 2024
250 enrolled
PsoriasisObesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Started Sep 2024
279 enrolled
Psoriatic ArthritisObesity
Worked on TALTZ at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.